Maximum quantity allowed is 999
请选择数量
CAS RN: 75330-75-5 | 產品號碼: L0214
產品規格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 166.0 to 170.0 °C |
| Specific rotation [a]20/D | +320 to +340 deg(C=0.5, CH3CN) |
性質
| 熔點 | 179 °C |
| 比旋光 [α]D | 320° (C=0.5,CH3CN) |
| 水溶性 | Insoluble |
| Degree of solubility in water | 0.4 mg/l 25 °C |
| 溶解性（可溶於） | Ethanol, Methanol |
GHS
| 危險性說明 | H413 : May cause long lasting harmful effects to aquatic life. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. |
相關法規
| RTECS # | EK7907000 |
運輸資料
| HS編碼* | 2932.20-000 |
Application
Lovastatin: A Potent HMG-CoA Reductase Inhibitor
Lovastatin is a potent 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. It was first isolated from in a fermentation broth of Aspergillus terreus in 1978, and taken into clinical development as potential agents for lowering LDL cholesterol. Lovastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding active beta-hydroxy acid. The active acid inhibits the action of enzyme HMG-CoA reductase that catalyzes the rate-limiting step in cholesterol biosynthesis, resulting in the reduction of low-density-lipoprotein (LDL) and total cholesterol levels. (The product is for research purpose only.)
References
- Case history: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors (a review)
- Analysis of 5 HMG-CoA reductase inhibitors-atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies
- Chromatography-mass spectrometry methods for the quantitation of statins in biological samples (a review)
- Solubility of lovastatin in a family of six alcohols: ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol, and 1-octanol
Application
HMG-CoA Reductase Inhibitors (Statins)
Lovastatin is a potent 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. It was first isolated from in a fermentation broth of Aspergillus terreus in 1978, and taken into clinical development as potential agents for lowering LDL cholesterol. Lovastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding active beta-hydroxy acid. The active acid inhibits the action of enzyme HMG-CoA reductase that catalyzes the rate-limiting step in cholesterol biosynthesis, resulting in the reduction of low-density-lipoprotein (LDL) and total cholesterol levels. (The product is for research purpose only.)
References
- Case history: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors (a review)
- Analysis of 5 HMG-CoA reductase inhibitors-atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies
- Chromatography-mass spectrometry methods for the quantitation of statins in biological samples (a review)
- Solubility of lovastatin in a family of six alcohols: ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol, and 1-octanol
考研文獻
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。